Interferon beta-1a Completed Phase N/A Trials for Relapsing Remitting Multiple Sclerosis (RRMS)

IndicationsStatusPurposePhase
CompletedNot AvailableNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT02247310BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
NCT01080027Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
NCT03347370A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
NCT01075880Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
NCT02823951Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
NCT01142518An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
NCT01142453An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
NCT01142492A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)